Is there evidence of potential overtreatment of glycaemia in elderly people with type 2 diabetes? Data from the GUIDANCE study
Müller, Nicolle; Khunti, Kamlesh; Kuss, Oliver; Lindblad, Ulf; Nolan, John J.; Rutten, Guy EHM; Trento, Marina; Porta, Massimo; Roth, Johannes; Charpentier, Guillaume; Jörgens, Viktor; Müller, Ulrich A.
(2017) Acta Diabetologica, volume 54, issue 2, pp. 209 - 214
(Article)
Abstract
Aims: We used data from the GUIDANCE Study to determine the care of people with type 2 diabetes according to age and accompanying cardiovascular diseases and to assess indicators of overtreatment of glycaemia.Methods: The GUIDANCE study was a retrospective, cross-sectional study from 2009–2010 based on the records of 7597 people
... read more
in France, Belgium, Italy, the Netherlands, Sweden, UK, Ireland and Germany. We analysed the level of metabolic control achieved and blood glucose-lowering medication used in different age groups and in relation to accompanying diseases.Results: 4.459 patients (59.1%) were 65 years or older. Their HbA1c levels were similar to those with
show less
Download/Full Text
The full text of this publication is not available.
Keywords: HbA1c, Hypoglycaemia, Overtreatment, Type 2 diabetes, Internal Medicine, Endocrinology, Diabetes and Metabolism, Endocrinology, Journal Article
ISSN: 0940-5429
Publisher: Springer-Verlag Italia
Note: Funding Information: KK acknowledges the support from the National Institute for Health Research Collaboration for Leadership in Applied Health Research and Care—East Midlands (NIHR CLAHRC—EM), the Leicester Clinical Trials Unit and the NIHR Leicester-Loughborough Diet, Lifestyle and Physical Activity Biomedical Research Unit. KK has acted as a consultant and speaker for Novartis, Novo Nordisk, Sanofi-Aventis, Lilly and Merck Sharp & Dohme. He has received grants in support of investigator and investigator initiated trials from Novartis, Novo Nordisk, Sanofi-Aventis, Lilly, Pfizer, Boehringer Ingelheim and Merck Sharp & Dohme. KK has received funds for research, honoraria for speaking at meetings and has served on advisory boards for Lilly, Sanofi-Aventis, Merck Sharp & Dohme and Novo Nordisk. Funding Information: The GUIDANCE study was funded by the European Association for the Study of Diabetes from a grant from Merck & Co. (Whitehouse Station, NJ). Merck scientists participated in the initial conceptualisation and protocol development but were not involved in the conduct of the study or in the analysis and interpretation of the data collected. The present analysis was funded by the Diabetes Centre Thuringia, Germany, a non-profit-making organisation for diabetes education and research. Publisher Copyright: © 2016, Springer-Verlag Italia.
(Peer reviewed)